Durham, United States
Ribometrix Inc., founded in 2014, is a pioneering player in the biotechnology sector focused on harnessing the potential of RNA-targeting therapeutics. The company's slogan, "Combining the proven power of small molecules with the promise of RNA targeting to create a new class of therapeutics," reflects its innovative approach. Headquartered in the United States, Ribometrix operates from its scientific offices at the renovated Biolabs Space in Durham, with additional offices in Chapel Hill and Boston.
The company stands at the intersection of biotechnology, health care, and pharmaceutical industries, developing small molecule drugs that target functional 3D RNA structures. Ribometrix's last investment was a $7.80M Early VC round on 01 September 2019, backed by notable investors including SV Health Investors, Illumina Ventures, and Dementia Discovery Fund. This investment underscores strong confidence in Ribometrix's cutting-edge therapeutic platform and its potential to address critical unmet medical needs.
